131 related articles for article (PubMed ID: 25749039)
1. Recurrent SKIL-activating rearrangements in ETS-negative prostate cancer.
Annala M; Kivinummi K; Tuominen J; Karakurt S; Granberg K; Latonen L; Ylipää A; Sjöblom L; Ruusuvuori P; Saramäki O; Kaukoniemi KM; Yli-Harja O; Vessella RL; Tammela TL; Zhang W; Visakorpi T; Nykter M
Oncotarget; 2015 Mar; 6(8):6235-50. PubMed ID: 25749039
[TBL] [Abstract][Full Text] [Related]
2. ETS transcription factor ESE1/ELF3 orchestrates a positive feedback loop that constitutively activates NF-κB and drives prostate cancer progression.
Longoni N; Sarti M; Albino D; Civenni G; Malek A; Ortelli E; Pinton S; Mello-Grand M; Ostano P; D'Ambrosio G; Sessa F; Garcia-Escudero R; Thalmann GN; Chiorino G; Catapano CV; Carbone GM
Cancer Res; 2013 Jul; 73(14):4533-47. PubMed ID: 23687337
[TBL] [Abstract][Full Text] [Related]
3. The role of SPINK1 in ETS rearrangement-negative prostate cancers.
Tomlins SA; Rhodes DR; Yu J; Varambally S; Mehra R; Perner S; Demichelis F; Helgeson BE; Laxman B; Morris DS; Cao Q; Cao X; Andrén O; Fall K; Johnson L; Wei JT; Shah RB; Al-Ahmadie H; Eastham JA; Eggener SE; Fine SW; Hotakainen K; Stenman UH; Tsodikov A; Gerald WL; Lilja H; Reuter VE; Kantoff PW; Scardino PT; Rubin MA; Bjartell AS; Chinnaiyan AM
Cancer Cell; 2008 Jun; 13(6):519-28. PubMed ID: 18538735
[TBL] [Abstract][Full Text] [Related]
4. Androgen regulation of ETS gene fusion transcripts in prostate cancer.
Gasi D; Trapman J
Methods Mol Biol; 2011; 776():335-48. PubMed ID: 21796535
[TBL] [Abstract][Full Text] [Related]
5. Upregulation of prostate-derived Ets factor by luteolin causes inhibition of cell proliferation and cell invasion in prostate carcinoma cells.
Tsui KH; Chung LC; Feng TH; Chang PL; Juang HH
Int J Cancer; 2012 Jun; 130(12):2812-23. PubMed ID: 21780100
[TBL] [Abstract][Full Text] [Related]
6. TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming.
Iljin K; Wolf M; Edgren H; Gupta S; Kilpinen S; Skotheim RI; Peltola M; Smit F; Verhaegh G; Schalken J; Nees M; Kallioniemi O
Cancer Res; 2006 Nov; 66(21):10242-6. PubMed ID: 17079440
[TBL] [Abstract][Full Text] [Related]
7. ETS fusion genes in prostate cancer.
Gasi Tandefelt D; Boormans J; Hermans K; Trapman J
Endocr Relat Cancer; 2014 Jun; 21(3):R143-52. PubMed ID: 24659477
[TBL] [Abstract][Full Text] [Related]
8. ETS gene fusions in prostate cancer: from discovery to daily clinical practice.
Tomlins SA; Bjartell A; Chinnaiyan AM; Jenster G; Nam RK; Rubin MA; Schalken JA
Eur Urol; 2009 Aug; 56(2):275-86. PubMed ID: 19409690
[TBL] [Abstract][Full Text] [Related]
9. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer.
Tomlins SA; Laxman B; Dhanasekaran SM; Helgeson BE; Cao X; Morris DS; Menon A; Jing X; Cao Q; Han B; Yu J; Wang L; Montie JE; Rubin MA; Pienta KJ; Roulston D; Shah RB; Varambally S; Mehra R; Chinnaiyan AM
Nature; 2007 Aug; 448(7153):595-9. PubMed ID: 17671502
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of chromosomal rearrangements involving non-ETS genes in prostate cancer.
Kluth M; Galal R; Krohn A; Weischenfeldt J; Tsourlakis C; Paustian L; Ahrary R; Ahmed M; Scherzai S; Meyer A; Sirma H; Korbel J; Sauter G; Schlomm T; Simon R; Minner S
Int J Oncol; 2015 Apr; 46(4):1637-42. PubMed ID: 25625310
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic targeting of SPINK1-positive prostate cancer.
Ateeq B; Tomlins SA; Laxman B; Asangani IA; Cao Q; Cao X; Li Y; Wang X; Feng FY; Pienta KJ; Varambally S; Chinnaiyan AM
Sci Transl Med; 2011 Mar; 3(72):72ra17. PubMed ID: 21368222
[TBL] [Abstract][Full Text] [Related]
12. ETS rearrangements in prostate cancer.
Rubin MA
Asian J Androl; 2012 May; 14(3):393-9. PubMed ID: 22504874
[TBL] [Abstract][Full Text] [Related]
13. Oncogenic ETS Factors in Prostate Cancer.
Nicholas TR; Strittmatter BG; Hollenhorst PC
Adv Exp Med Biol; 2019; 1210():409-436. PubMed ID: 31900919
[TBL] [Abstract][Full Text] [Related]
14. TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer.
Tomlins SA; Mehra R; Rhodes DR; Smith LR; Roulston D; Helgeson BE; Cao X; Wei JT; Rubin MA; Shah RB; Chinnaiyan AM
Cancer Res; 2006 Apr; 66(7):3396-400. PubMed ID: 16585160
[TBL] [Abstract][Full Text] [Related]
15. Rearrangement of the ETS genes ETV-1, ETV-4, ETV-5, and ELK-4 is a clonal event during prostate cancer progression.
Alder D; Braun M; Nikolov P; Boehm D; Scheble V; Menon R; Fend F; Kristiansen G; Perner S; Wernert N
Hum Pathol; 2012 Nov; 43(11):1910-6. PubMed ID: 22569213
[TBL] [Abstract][Full Text] [Related]
16. Over-expression of lipocalin 2 promotes cell migration and invasion through activating ERK signaling to increase SLUG expression in prostate cancer.
Ding G; Fang J; Tong S; Qu L; Jiang H; Ding Q; Liu J
Prostate; 2015 Jun; 75(9):957-68. PubMed ID: 25728945
[TBL] [Abstract][Full Text] [Related]
17. Common gene rearrangements in prostate cancer.
Rubin MA; Maher CA; Chinnaiyan AM
J Clin Oncol; 2011 Sep; 29(27):3659-68. PubMed ID: 21859993
[TBL] [Abstract][Full Text] [Related]
18. ETV4 promotes metastasis in response to activation of PI3-kinase and Ras signaling in a mouse model of advanced prostate cancer.
Aytes A; Mitrofanova A; Kinkade CW; Lefebvre C; Lei M; Phelan V; LeKaye HC; Koutcher JA; Cardiff RD; Califano A; Shen MM; Abate-Shen C
Proc Natl Acad Sci U S A; 2013 Sep; 110(37):E3506-15. PubMed ID: 23918374
[TBL] [Abstract][Full Text] [Related]
19. Differential expression of ETS family members in prostate cancer tissues and androgen-sensitive and insensitive prostate cancer cell lines.
Adler D; Lindstrot A; Langer B; Buettner R; Wernert N
Int J Mol Med; 2011 Jul; 28(1):89-93. PubMed ID: 21491078
[TBL] [Abstract][Full Text] [Related]
20. ETS factors in prostate cancer.
Qian C; Li D; Chen Y
Cancer Lett; 2022 Apr; 530():181-189. PubMed ID: 35033589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
